P21

P21 was rationally engineered by epitope mapping of CNTF's active region, corresponding to CNTF residues 148–151 (core sequence DGGL). The final sequence (Ac-DGGLAG-NH₂) incorporates N-terminal acetylation and a C-terminal amide for stability, with an adamantane moiety attached to the fifth residue to increase lipophilicity. In silico docking and biochemical analysis characterized binding interactions at the CNTF/LIF receptor complex. Pharmacokinetic assays examined oral stability and bioavailability in simulated physiological fluids, informing subsequent in-vivo study designs.

In cultured neurons and rodent brain tissue, P21 has been examined in the context of CNTF/LIF-related signaling. Biochemical assays in rodent hippocampus have measured pCREB and BDNF levels, as well as GSK-3β Ser9 phosphorylation, following P21 treatment. Kazim et al. (2016) reviewed evidence for P21's interaction with LIF-activated STAT3 signaling and its relationship to downstream neurotrophic pathways. In vitro, Mottolese et al. (2024) measured neuronal progenitor proliferation (BrdU incorporation), survival (TUNEL assays), and maturation (NeuN+ counts) in CDKL5-deficient human neuroblastoma cells treated with P21. These cellular assays characterize how P21 engages intracellular neurotrophic signaling at the molecular level.

P21 has been examined in transgenic mouse models carrying Alzheimer's-associated pathology. Baazaoui and Iqbal (2017) conducted a study in which 3×Tg-AD mice received P21-supplemented chow for several months; hippocampal synaptic proteins (PSD-95, synaptophysin) and the dendritic marker MAP2 were measured by immunohistochemical and Western blot assays. Wei et al. (2021) administered P21 orally from birth through weaning in 3×Tg-AD mice and measured hippocampal signaling proteins — including phosphorylated CREB, BDNF, and pathway components of PLC/PKC, MEK/ERK, and PI3K/Akt — by Western blot. Falangola et al. (2026) applied diffusion MRI to 3×Tg-AD mice receiving early P21 treatment, measuring brain microstructural parameters to characterize white-matter architecture. Across these studies, behavioral tasks (Morris water maze, novel object recognition) were recorded alongside the primary synaptic and neurogenic endpoints.

Kazim et al. (2017) studied P21 in the Ts65Dn Down syndrome mouse model, administering the peptide to pregnant dams and neonatal pups. The study measured developmental milestone timing and hippocampal-dependent behavioral task performance in offspring. At the molecular level, hippocampal BDNF gene transcription (RT-PCR), CREB phosphorylation (Western blot), and GSK-3β Ser9 phosphorylation were assessed in treated versus untreated Ts65Dn animals. Synaptic markers were characterized by immunohistochemistry. This study examined P21 in the context of the disrupted neurogenesis and synaptic plasticity associated with trisomy 21 in a preclinical model.

Mottolese et al. (2024) used SH-SY5Y neuroblastoma cells lacking CDKL5 to model a rare neurodevelopmental disorder; cells were treated with P21 and proliferation, survival, and maturation markers were measured. In the companion in vivo experiment, Cdkl5 knockout mice received oral P21 and cortical neuron density along with TrkB-Akt-GSK-3β pathway components were assessed by immunohistochemistry and Western blot. An earlier study by Li et al. (2010) measured hippocampal neurogenesis markers (BrdU incorporation, NeuN+ cell counts) and associated behavioral assay performance in rodents, characterizing P21 in the adult neurogenesis context.